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Background
In HIV infected patients there is increasing evidence of
hypertension and microalbuminuria, two important risk
factors for renal and cardiovascular disease (CVD). Anti-
hypertensive drugs inhibiting the renin-angiotensin sys-
tem exert an antiproteinuric effect. Telmisartan, an
angiotensin II receptor blocker partial agonist of the
PPAR-g approved for the treatment of hypertension,
seems to exert a nephro-protective effect independent of
blood pressure reduction in the general population. Aim
of the study was to evaluate kidney-protective effects of
telmisartan in hypertensive HIV+patients with
microalbuminuria.
Methods
8 Caucasian male HIV+ patients cART treated without
therapeutic changes for over 12 months and recent diag-
nosis of mild hypertension, were treated with telmisar-
tan 80 mg daily. They had suppressed viremia and CD4
cell count > 300 cell/ml up on 6 month, and microalbu-
minuria >5 mg/l. Systolic (SBP) and diastolic (DBP)
blood pressure, triglycerides (TGs), total cholesterol
(TCh), HDL (HDL-C) and LDL (LDL-C) cholesterol,
CRP, ESR, microalbuminuria, MDRD-GFR, cystatin-C,
IL-18, VEGF and endothelin-1 were measured at base-
line (T0), one (T1), three (T3) and six months (T6). All
the statistical analysis was performed with the SPSS
Advanced Statistical 7.5 Software.
Results
Treatment with telmisartan improved SBP and DBP
values at T1 yet (p = 0,001). Microalbuminuria were
statistically decreased at T1 (p = 0,006) and further on
T6 (p = 0,0001), whereas MDRD-GFR was statistically
augmented (p = 0,03). Cystatin-C, endothelin-1 and
VEGF were statistically reduced at T3 (p = 0,0001; p =
0,01 and p = 0,0045 respectively) and at T6. TG, TCh,
LDL-C levels decreased with statistical significance at
T6 (p = 0,003; p = 0,03 and p = 0,02 respectively), while
HDL-C increased at T6 (p = 0,04). ESR, PCR and IL-18
decreased at T6 (p = 0,04; p = 0,006 and p = 0,02
respectively).
Discussion
Telmisartan was well tolerated and effective to improve
hypertension and lipid metabolism. Decreased microal-
buminuria and cystatin-C with increased MDRD-GFR
are indicative of nephro-protective effects of telmisartan.
Mechanisms causing microalbuminuria in HIV+ patients
could be related to infection, chronic inflammation and
endothelial dysfunction. Decreased endothelin-1 and
VEGF in this study may be related to an endothelial
protective effect of telmisartan. These data confirm
renal and endothelial protective effects of telmisartan
also in HIV+ patients.
Published: 11 May 2010
doi:10.1186/1742-4690-7-S1-P64
Cite this article as: Ucciferri et al.: Hypertension and microalbuminuria
in HIV infected patients: beneficial effects of the treatment with
telmisartan. Retrovirology 2010 7(Suppl 1):P64.
* Correspondence: ucciferri@tiscali.it
Infectious Disease Clinic, Department of Medicine and Science of Aging, “G.
d’Annunzio” University, Chieti, Italy
Ucciferri et al. Retrovirology 2010, 7(Suppl 1):P64
http://www.retrovirology.com/content/7/S1/P64
© 2010 Ucciferri et al; licensee BioMed Central Ltd.
